DAWN vs SRPT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
DAWN shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Mixed signals with both opportunities and risks present.
Sarepta Therapeutics exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a near-total failure of fundamental health metrics. The company is grappling with negative gross margins (-7.43%) and a catastrophic collapse in revenue growth (-32.70% YoY), suggesting a failing business model or significant product loss. While the current ratio remains adequate, the combination of negative profitability, bearish insider selling, and a 60% one-year price decline creates a high-risk profile. The stock is currently trading near its analyst target price, leaving little room for upside given the deteriorating fundamentals.
Compare Another Pair
Related Comparisons
DAWN vs SRPT: Head-to-Head Comparison
This page compares Day One Biopharmaceuticals, Inc. (DAWN) and Sarepta Therapeutics, Inc. (SRPT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.